Amidst the coronavirus pandemic people in many countries worry whether too many crucial elements in their healthcare systems have been outsourced, in particular to China. But that's not a concern for German pharma, says Han Steutel, president of the German Association of Research-Based Pharmaceutical Companies (VfA).
"Germany is one of the world's strongest production locations where innovative, patented medications are concerned," Mr Steutel explained, adding: "Even amidst the stress test of the corona pandemic, Germany has remained capable of delivering and has exported significantly more patented medical products to China than it has imported from that country."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze